A Phase II Study on the Effect of Taurisolo® Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study.

2022-04-29
Cells 11(9)
- Stefano Sanduzzi Zamparelli
- Ludovica Capitelli
- Nicola Coppola
- Claudia Venditto
- Ciro Santoro
- Giuseppe Annunziata
- Dario Bruzzese
- Nunzia Cuomo
- Ivan Gentile
- Marialuisa Bocchino
- Alessandro Sanduzzi Zamparelli

PubMed: 35563805
DOI: 10.3390/cells11091499

Study Design

Type: Clinical Trial
Sample size: n = 19
Population: hospitalized patients suffering from SARS-CoV-2 pneumonia
Methods: phase II multicentric clinical trial (TAEROVID-19) during the first wave of the COVID-19 pandemic, Taurisolo® aerosol formulation
Blinding: Open-label
Funding: Unclear

Background

Polyphenols are the largest class of bioactive compounds in plants, which are synthesized as secondary metabolites. In the last few years, interesting studies have demonstrated the efficacy of polyphenols against coronavirus infections.

Methods

we conducted a phase II multicentric clinical trial (TAEROVID-19) during the first wave of the COVID-19 pandemic in order to assess the safety and feasibility of Taurisolo^® aerosol formulation in hospitalized patients suffering from SARS-CoV-2 pneumonia.

Results

we observed a rapid decline of symptoms and a low rate of intensive care in patients treated with Taurisolo^®, with a faster decline of symptoms.

Conclusions

This is the first trial assessing the safety and feasibility of Taurisolo^® aerosol formulation. We could argue that this treatment could act as an add-on therapy in the treatment of COVID-19 patients, owing to both its anti-inflammatory and antioxidant effects. Further controlled trials are needed, which may be of interest to evaluate the compound's efficacy.